Pfizer shares resistant despite missing estimates on 2017 guidance

31 January 2017

US pharma giant Pfizer (NYSE: PFE) missed analysts’ estimates with its forecast for revenue in 2017 as it presented a set of results which showed the increasing impact of competition and the company’s focus on mergers and acquisitions (M&A).

The full-year 2016 revenue figure was $52.8 billion, 8% up on the previous year, but the company’s adjusted income for 2016, of $7.22 billion, was up a more marginal 4% on 2015. Adjusted diluted earnings-per-share (EPS) were $1.17, compared to 2015’s $1.11.

Pfizer’s forecast for revenue in 2017 fell short of analysts’ predictions. Estimates compiled by Bloomberg had predicted $54.3 billion, but the company is only confident that it will be between $52 billion and $54 billion.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK